记者丨 高江虹 实习生陈晓冉 编辑丨张伟贤 这大概是美妆巨头雅诗兰黛二十年来最大的亏损。 8月20日晚间，雅诗兰黛发布截至6月30日的2025财年Q4及全年业绩报告。尽管已积极调整战 略方向，但雅诗兰黛业绩依旧低迷。2025财年，其净销售额为143.26亿美元，同比下滑8%， 净利润同比暴跌390%，从上一年的盈利3.9亿美元变为亏损11.33亿美元。 这份业绩一出炉，股价立即跳水。当日，雅诗兰黛美股盘前一度跌近15%。截至美东时间周五 收盘，股价为91.23美元，而2022年年初时其股价曾高达374.2美元。 华尔街金融巨头摩根士丹利发布研报，维持对雅诗兰黛股票的"中性"看跌评级， 并预计雅诗 兰黛股价将进一步下跌， 未来12个月内潜在跌幅超过20%。 对此，雅诗兰黛管理层对此泰然自若，"业绩整体符合预期，"雅诗兰黛集团总裁兼首席执行官 司泰峰（Stéphane de La Faverie）表示，有信心在2026财年实现有机销售额增长，开始重建 营运盈利能力，并在未来几年实现稳健的两位数调整后营业利润率。 值得关注的是，自2026财年Q1起，雅诗兰黛集团调整区域架构，未来中国大陆将作为独立地 区进行业绩列报 ...

21世纪经济报道记者高江虹、实习生陈晓冉 护肤品作为曾经的顶梁柱，这次摔得最狠。财报直指 Estée Lauder 和 La Mer 两大核心品牌拖了后腿。 具体来看，亚洲旅游零售业务疲软，中国消费者出国消费的热情降温，免税店订单跟着缩水；Dr.Jart + 在中韩市场第四季度业绩也远不如预期。唯有The Ordinary 靠着精准触达消费者，还能保持中个位数增 长。 这大概是美妆巨头雅诗兰黛二十年来最大的亏损。 8月20日晚间，雅诗兰黛发布截至6月30日的2025财年Q4及全年业绩报告。尽管已积极调整战略方向， 但雅诗兰黛业绩依旧低迷。2025财年，其净销售额为143.26亿美元，同比下滑8%，净利润同比暴跌 390%，从上一年的盈利3.9亿美元变为亏损11.33亿美元。 这份业绩一出炉，股价立即跳水。当日，雅诗兰黛美股盘前一度跌近15%。目前雅诗兰黛的股价仅为 87.72美元，而2022年年初时其股价曾高达374.2美元。 华尔街金融巨头摩根士丹利发布研报，维持对雅诗兰黛股票的"中性"看跌评级，并预计雅诗兰黛股价将 进一步下跌，未来12个月内潜在跌幅超过20%。 对此，雅诗兰黛管理层对此泰然自若，"业绩整 ...

Group 1 - L'Oréal is reportedly interested in acquiring the UK skincare brand Medik8, which has sparked discussions in the industry [1] - Medik8 is known for its "CSA skincare philosophy" and has gained popularity for its "morning C, evening A" concept [2] - Medik8's sales are projected to grow by 50% in 2024, with global revenue expected to exceed $100 million (approximately 720 million RMB) in 2025 [4] Group 2 - L'Oréal's skincare division has been expanding rapidly, with sales surpassing 7 billion euros (approximately 54.8 billion RMB) in 2024, making it one of the fastest-growing segments of the company [6] - Estée Lauder's brand The Ordinary has entered the Chinese market, emphasizing high-concentration ingredient formulations at affordable prices [6] - Both L'Oréal and Estée Lauder are targeting a trend where consumers prefer effective and cost-efficient products [8] Group 3 - Local skincare brands like Winona and Yuze have established a strong market presence in China, leveraging a "medical-research co-creation" model [9] - The evolving consumer awareness in China indicates that mere ingredient stacking is insufficient; product texture, scientific formulation, and brand storytelling are becoming increasingly important [9] - For L'Oréal, building a distribution channel for Medik8 in China is crucial for market entry, while The Ordinary faces challenges from well-established local competitors [10]

Core Viewpoint - The company, which owns The Ordinary and Clinique brands, expects a sales decline of 8% to 9% this year, which is worse than Wall Street's expectations [1] Group 1: Sales and Financial Performance - The anticipated sales decline is attributed to trade turmoil and a challenging economic outlook, exacerbating existing deep-rooted challenges faced by the beauty giant [1] - The company's stock rose by 5% in pre-market trading on Thursday, despite a year-to-date decline of 20% for Estée Lauder, compared to a 5.3% drop in the S&P 500 index [1] Group 2: Strategic Initiatives - The company has indicated early signs that its turnaround plan is showing effectiveness, suggesting potential for recovery if issues are adequately addressed [1] - Recent tariff measures have been implemented to mitigate potential negative impacts related to the economic challenges [1]